NUNZ — Nunzia Pharmaceutical Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nunzia Pharmaceutical Corporation is a pharmaceutical company. The Company focuses on development and delivery of pharmaceutical and nutraceutical-based therapies for the behavioral symptoms of Autistic Spectrum of Disorders (ASDs) and related conditions, such as Fragile X syndrome, as well as common anxiety-based disorders. The Company has developed NUNZIA, which is a combination of 16 vitamins, minerals and herbs which directly focuses and targets the hippocampus area of the brain, where all anxiety-based disorders originate.
Directors
- R. Steve Mills CEO (54)
- Kingman Hitz CFO (61)
- Roger Kron COO (48)
- G.David Henry DRC (62)
- Mary Pohlmeier DRC (61)
- Robin Sandifer DRC (72)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- December 11th, 1986
- Public Since
- January 23rd, 1995
- No. of Shareholders
- 646
- No. of Employees
- 4
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 434,565,578
- Address
- 1627 WEST 14TH STREET, LONG BEACH, 90813
- Web
- https://www.vcgi.com
- Phone
- +1 7146099117
- Auditors
- KBA Group LLP
Upcoming Events for NUNZ
Similar to NUNZ
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 22:23 UTC, shares in Nunzia Pharmaceutical are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Nunzia Pharmaceutical last closed at $0.00 and the price had moved by -99.97% over the past 365 days. In terms of relative price strength the Nunzia Pharmaceutical share price has underperformed the S&P500 Index by -99.97% over the past year.
There is no consensus recommendation for this security.
Find out moreNunzia Pharmaceutical does not currently pay a dividend.
Nunzia Pharmaceutical does not currently pay a dividend.
Nunzia Pharmaceutical does not currently pay a dividend.
To buy shares in Nunzia Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Nunzia Pharmaceutical had a market capitalisation of .
Here are the trading details for Nunzia Pharmaceutical:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NUNZ
Based on an overall assessment of its quality, value and momentum Nunzia Pharmaceutical is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nunzia Pharmaceutical. Over the past six months, its share price has underperformed the S&P500 Index by -99.97%.
As of the last closing price of $0.00, shares in Nunzia Pharmaceutical were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nunzia Pharmaceutical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nunzia Pharmaceutical's management team is headed by:
- R. Steve Mills - CEO
- Kingman Hitz - CFO
- Roger Kron - COO
- G.David Henry - DRC
- Mary Pohlmeier - DRC
- Robin Sandifer - DRC